Dihexa Blog — Evidence-Based 2026 UK Reviews

Rigorous, fully-referenced condition-by-condition reviews of where Dihexa (PNB-0408) sits in the evidence hierarchy for brain fog and cognitive health — alongside mechanism, BDNF and nootropic science. Browse the latest review below, then explore by topic.

Digital Life, Screens & Attention

Brain fog from modern digital life — “brain rot”, screen time, doomscrolling, social media and the trained attention span.

Brain Rot and Digital Brain Fog – Dihexa evidence review on screen time, doomscrolling and attention
NewDigital Life & Cognitive Neuroscience 1 July 2026

Dihexa & “Brain Rot”: Digital Brain Fog from Screen Time, Doomscrolling & Social Media (2026 Review)

Can a synaptogenic peptide reverse “brain rot” or digital brain fog? A 2026 UK review tied to Oxford’s 2024 Word of the Year: how screen time, media multitasking and doomscrolling fragment attention, the anterior-cingulate grey-matter research, the dopamine and sleep mechanisms, the reassuring evidence on reversibility — and why digital hygiene, not a peptide, comes first…

Read the full review →

Environmental, Weather & Toxin Exposure

Brain fog from what you breathe, drink and live among — microplastics, heat & dehydration, air pollution and mould.

Microplastics and Nanoplastics in the Brain – Dihexa evidence review on the 2025 human-brain study, the dementia link and cognition
NewEnvironmental Toxin & Cognitive Neuroscience 7 July 2026

Dihexa for Microplastics Brain Fog: Nanoplastics, the Brain & the 2026 UK Review

A February 2025 Nature Medicine study found micro- and nanoplastics accumulating in the human brain — ~50% more than in 2016, and far more in dementia brains — the “plastic spoon’s worth” that went viral. Do microplastics cause brain fog? A 2026 UK review of the blood-brain-barrier route, bottled-water nanoplastics (~240,000/litre), the Duke alpha-synuclein / Parkinson’s work, the mouse neuroinflammation data, the honest limits (correlation, the contested spoon, the WHO caveat), the UK regulatory gap and how to cut your exposure — and why a pro-proliferative peptide is the wrong answer to a particle problem…

Read the full review →
Dehydration and Heat Brain Fog – Dihexa evidence review tied to the June 2026 UK heatwave
NewHeat, Hydration & Cognitive Neuroscience 30 June 2026

Dihexa for Dehydration & Heat Brain Fog: The 2026 UK Heatwave, Hydration, Cognition & the HGF/c-Met Question

Can a synaptogenic peptide help dehydration or heat brain fog? A 2026 UK review tied to the record-breaking June 2026 heatwave and UKHSA red heat-health alerts: how a 1–2% body-water loss impairs attention and working memory, how dehydration shrinks brain tissue, the hyperthermia hit, the cortisol mechanism — and why rehydrating and cooling down, not a peptide, comes first…

Read the full review →

Post-Viral, Fatigue & Dysautonomia

Brain fog after infection — EBV, Long COVID, ME/CFS, Lyme and PoTS.

Autoimmune, Gut & Inflammatory

Where immune activity and the gut meet cognition.

Hay Fever and Antihistamine Brain Fog – Dihexa evidence review
NewAllergy & Cognitive Neuroscience 29 June 2026

Dihexa for Hay Fever & Antihistamine Brain Fog: Allergic Rhinitis, Histamine, the Anticholinergic-Dementia Link & the 2026 UK Review

Around 16 million people in the UK have hay fever — and “hay fever brain fog” has two sources: the allergy and the medicine. Sedating antihistamines like chlorphenamine (Piriton) and diphenhydramine cross into the brain and block the histamine that keeps you alert. A 2026 UK review of the histamine-and-wakefulness science, the hippocampal-prefrontal evidence, the anticholinergic-burden & dementia question, why non-drowsy antihistamines come first — and why treating the allergy, not a peptide, comes first…

Read the full review →
Sjögren's Syndrome Brain Fog – Dihexa evidence review
Autoimmune & Cognitive Neuroscience 23 June 2026

Dihexa for Sjögren’s Syndrome Brain Fog: Sjögren’s Fog, the Ianalumab NEPTUNUS Phase 3, Nipocalimab DAHLIAS & the 2026 UK Review

“My eyes and mouth are dry — but it’s the fog that’s wrecking my life.” Up to 500,000 people in the UK live with Sjögren’s — the second most common autoimmune rheumatic disease after rheumatoid arthritis — and brain fog and fatigue routinely rank above dryness for what disrupts daily life, with measurable cognitive impairment in ~44–50%. After decades with no disease-modifying drug, 2024–2026 finally delivered the first targeted therapies: Novartis’ ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&J’s nipocalimab was positive in the Phase 2 DAHLIAS trial (The Lancet). A 2026 UK review of the neuroinflammation / white-matter / small-fibre mechanism, the 2025 BSR guideline, the BDNF / HGF/c-Met case, the elevated lymphoma risk vs pro-proliferative c-Met — and why specialist care, not a peptide, comes first…

Read the full review →
Gut-Brain Axis Brain Fog – Dihexa evidence review
Microbiome & Gut-Brain Neuroscience 16 June 2026

Dihexa for Gut-Brain Axis Brain Fog: IBS, SIBO, Leaky Gut, the Microbiome & the 2026 UK Review

“My gut’s a mess and so is my head — are they connected?” Increasingly, the science says they can be. The gut and brain talk constantly along the vagus nerve and through immune, hormonal and short-chain-fatty-acid signals — the microbiota–gut–brain axis — and a disturbed microbiome in IBS (which affects 10–20% of people), SIBO, “leaky gut” or long COVID can cloud thinking. A 2026 UK review of the 2024 “Gut Feelings” probiotic-cognition RCT (weak working-memory benefit), the long-COVID Lactobacillus paracasei PS23 brain-fog trial (NCT06348212), the gut–BDNF link, NICE CG61 and the low-FODMAP/probiotic evidence, plus HGF’s dual role in gut-lining repair and brain synaptogenesis — and why diagnosing and treating the gut comes first, not a peptide…

Read the full review →
Coeliac Disease and Gluten Brain Fog – Dihexa evidence review
Autoimmune & Gut-Brain Neuroscience 5 June 2026

Dihexa for Coeliac Disease & Gluten Brain Fog: The 2026 UK Review

Can Dihexa help coeliac disease or gluten brain fog? A 2026 UK evidence review of coeliac-related cognitive dysfunction, the Yelland 2017 brain fog study, the Lichtwark mucosal-healing cognition data, the Addolorato reversible cerebral hypoperfusion SPECT finding, the Sheffield gluten-neurology /…

Read the full review →

Nutrition & Metabolic

Deficiencies and metabolic drivers of cognitive symptoms.

Artificial Sweetener Brain Fog – Dihexa evidence review on aspartame, erythritol, diet soda, cognitive decline and the blood-brain barrier
NewNutrition, Metabolic & Cognitive Neuroscience 9 July 2026

Dihexa for Artificial Sweetener Brain Fog: Aspartame, Erythritol, Diet Soda & the 2026 UK Review

Do artificial sweeteners cause brain fog? A 2026 UK review of the October 2025 Neurology study linking high intake to ~62% faster cognitive decline, the aspartame methanol/phenylalanine/microglia neuroinflammation and BDNF/TrkB mechanism, the 2025 University of Colorado erythritol blood-brain-barrier and stroke study, the reverse-causation trap, the WHO/IARC verdict and the UK sugar-tax reformulation angle — versus Dihexa’s unproven HGF/c-Met synaptogenesis, and why switching to water beats a peptide…

Read the full review →
Keto and Low-Carb Brain Fog – Dihexa evidence review on the keto flu, ketones, beta-hydroxybutyrate and cognition
NewNutrition, Metabolic & Cognitive Neuroscience 8 July 2026

Dihexa for Keto & Low-Carb Brain Fog: Ketones, the Keto Flu, BHB & the 2026 UK Review

Does keto cause brain fog or clear it? A 2026 UK review separating the transient “keto flu” (a sodium/electrolyte problem that usually clears in 2–4 weeks) from the deeper ketone-cognition science: the 2026 “faster but less accurate” keto study, the Neurology reversible-memory-loss case report, the beta-hydroxybutyrate–BDNF HDAC story and its honest human limits, the MCI & Alzheimer’s ketone trials and low-carb diabetes remission data — versus Dihexa’s unproven HGF/c-Met synaptogenesis, and why salt and time beat a peptide…

Read the full review →
Seed Oils and Brain Fog – Dihexa evidence review on linoleic acid, omega-6, the seed-oil debate and cognition
NewNutrition & Cognitive Neuroscience 6 July 2026

Dihexa for Seed Oil Brain Fog: Linoleic Acid, Omega-6 & the 2026 UK Review

Do seed oils cause brain fog? A 2026 UK review of the “toxic seed oils” claim and the RFK Jr / MAHA beef-tallow debate, the January 2026 US dietary-guidelines shift, the NUTRITION 2025 biomarker study (higher linoleic acid, lower inflammation and cardiometabolic risk), the 2026 UK Biobank finding of ~18% lower dementia risk with higher plasma linoleic acid, the oversold omega-6:omega-3 ratio, the real culprits (oxidised frying oils and ultra-processed food) and NHS, BHF and HEART UK guidance — versus Dihexa’s unproven HGF/c-Met synaptogenesis, and why fixing the diet pattern comes first, not a peptide…

Read the full review →
Omega-3 and Fish Oil Brain Fog – Dihexa evidence review on DHA, EPA, the DO-HEALTH ageing trial and cognition
NewNutrition & Cognitive Neuroscience 5 July 2026

Dihexa vs Omega-3 & Fish Oil for Brain Fog: DHA, EPA & Cognition — The 2026 UK Review

Does omega-3 or fish oil help brain fog? A 2026 UK review of the February 2025 Nature Aging DO-HEALTH trial (1 g/day slowed biological ageing ~4 months), the Framingham red-blood-cell DHA data (~49% lower Alzheimer’s risk in the top group), the midlife hippocampal-volume study, the ~20% lower dementia risk from dietary omega-3, the APOE4 timing question and the honest atrial-fibrillation caveat with high-dose fish oil — versus Dihexa’s unproven HGF/c-Met synaptogenesis, and why oily fish comes first, not a peptide…

Read the full review →
Ultra-Processed Food Brain Fog – Dihexa evidence review on UPF, cognition and the gut–brain axis
NewNutrition, Diet & Cognitive Neuroscience 4 July 2026

Dihexa for Ultra-Processed Food Brain Fog: UPF, Cognition & the HGF/c-Met Question

Can Dihexa undo ultra-processed food brain fog? A 2026 UK review of the 2024 Neurology cognition-and-stroke study, the 2025 Neurology prodromal-Parkinson’s study (11+ servings a day, 2.5× risk), the 2026 dementia and systematic-review data, the NOVA classification and the UK SACN 2025 verdict, and the blood-sugar, gut–brain and inflammation mechanisms — versus Dihexa’s unproven HGF/c-Met synaptogenesis, and why cutting UPF comes first, not a peptide…

Read the full review →
Magnesium Deficiency Brain Fog – Dihexa evidence review
Nutritional & Metabolic Neuroscience 10 June 2026

Dihexa for Magnesium Deficiency Brain Fog: The 2025 Magnesium L–Threonate Trial, the NMDA–BDNF Mechanism & the UK Review

Can Dihexa help magnesium deficiency brain fog? A 2026 UK review of the 2025 Frontiers in Nutrition magnesium L–threonate (Magtein®) trial — better working and episodic memory and sleep in healthy adults — the 2023 UK Biobank study linking higher dietary magnesium to larger brain volumes, the foundational Slutsky 2010 Neuron synaptic–density work, the NMDA–receptor magnesium gate and BDNF/TrkB plasticity, why a normal blood test can hide a real shortfall, magnesium L–threonate vs glycinate, NHS intakes and the 400 mg rule — and why correcting magnesium comes first, not a peptide…

Read the full review →
Vitamin D Deficiency Brain Fog – Dihexa evidence review
Nutritional & Metabolic Neuroscience 9 June 2026

Dihexa for Vitamin D Deficiency Brain Fog: The 2026 Midlife Vitamin D–Tau Study, the VDR–BDNF Mechanism & the UK Review

Can Dihexa help vitamin D deficiency brain fog? A 2026 UK review of the April 2026 Galway/Boston study linking higher midlife vitamin D to lower Alzheimer’s tau years later, the classic Littlejohns 2014 dementia cohort (122% higher risk when severely deficient), the genuinely mixed VitaMIND and Finnish Vitamin D supplementation trials, the vitamin D receptor–CREB–TrkB–BDNF mechanism, NHS 25(OH)D thresholds and the 10 µg rule, UK winter risk groups — and why testing and correcting vitamin D comes first, not a peptide…

Read the full review →
Iron Deficiency and Anaemia Brain Fog – Dihexa evidence review
Nutritional & Metabolic Neuroscience 8 June 2026

Dihexa for Iron Deficiency & Anaemia Brain Fog: Low Ferritin, the 2025 Perimenopause Iron Study, Dopamine, Myelin & the 2026 UK Review

Can Dihexa help iron deficiency or anaemia brain fog? A 2026 UK review of the April 2025 University of Oklahoma Nutrients study showing non-anaemic women with "below expected" iron thought more slowly, iron deficiency without anaemia, the iron–dopamine (tyrosine hydroxylase) and myelin mechanism, hippocampal BDNF downregulation, NICE/NHS ferritin thresholds, oral and IV iron — and why checking ferritin and finding the cause comes first, not a peptide…

Read the full review →
Vitamin B12 Deficiency Brain Fog – Dihexa evidence review
Nutritional & Metabolic Neuroscience 7 June 2026

Dihexa for Vitamin B12 Deficiency Brain Fog: The "Normal B12" Study, Homocysteine & the 2026 UK Review

Can Dihexa help vitamin B12 deficiency brain fog? A 2026 UK review of the May 2026 UCSF Annals of Neurology study showing "normal" but lower active B12 is linked to slower thinking and more white-matter brain injury, NICE NG239, the homocysteine–DNA-methylation mechanism that suppresses hippocampal neurotrophins, the VITACOG brain-atrophy trial, pernicious anaemia, metformin and PPI depletion — and why replacing the B12 comes first, not a peptide…

Read the full review →

Drug & Substance-Induced

Medications and substances that can cloud thinking.

Caffeine, Coffee and Energy Drink Brain Fog – Dihexa evidence review on adenosine, the crash and withdrawal
NewStimulants, Diet & Cognitive Neuroscience 4 July 2026

Dihexa for Caffeine, Coffee & Energy Drink Brain Fog: Adenosine, the Crash, Withdrawal & the 2026 UK Review

“I run on coffee — so why am I foggier than ever?” The counter-intuitive answer: most caffeine brain fog is caffeine wearing off, not the caffeine. Caffeine blocks adenosine; when a dose fades, the backlog floods in as the crash, the between-dose slump and withdrawal — a 2022 Scientific Reports RCT even found withdrawal reduced working-memory brain activity. A 2026 UK review of the A1/A2A mechanism, tolerance, the 5–6h half-life “sleep tax”, the record 2026 dementia data (~35% lower risk at 2–3 cups), energy drinks and the under-16s ban, the EFSA 400 mg / NHS 200 mg limits, the BDNF link and the HGF/c-Met case — and why caffeine hygiene, not a peptide, comes first…

Read the full review →
SSRI and Antidepressant Brain Fog – Dihexa evidence review
Psychopharmacology & Cognitive Neuroscience 22 June 2026

Dihexa for SSRI & Antidepressant Brain Fog: Emotional Blunting, Memory & the 2026 UK Review

“My mood is better on my antidepressant — so why do I feel foggy, flat and half-switched-off?” A record 8.89 million people in England were prescribed antidepressants in 2024/25 (NHSBSA: 92.6 million items), and an estimated 40–60% of SSRI users report emotional blunting. Here is the twist that breaks the “just boost BDNF” fix: SSRIs generally raise BDNF and hippocampal neurogenesis — so antidepressant fog is not a synapse shortage a peptide refills. A 2026 UK review of the 2023 Cambridge reinforcement-learning study of emotional blunting, residual cognitive impairment, PSSD and its 2024 SNOMED CT recognition, NICE NG222 on stopping safely, the HGF/c-Met case — and why your prescriber, not a peptide, comes first…

Read the full review →
Vaping and Nicotine Brain Fog – Dihexa evidence review
Substance & Lifestyle Neuroscience 19 June 2026

Dihexa for Vaping & Nicotine Brain Fog: E-Cigarettes, Withdrawal, Cognition & the 2026 UK Review

“Why can’t I think straight when I vape — and why is the fog worse now I’m quitting?” Britain banned disposable vapes on 1 June 2025 and the Tobacco and Vapes Act 2025 is now law, yet ASH estimates ~1.1 million 11–17s have tried vaping. Nicotine is a paradox: it acutely sharpens attention via nicotinic receptors but dependence and withdrawal reliably fog memory and concentration — and a 2024 Psychopharmacology review links e-cigarettes to impaired memory and decision-making even in never-smokers. A 2026 UK review of the nicotine–BDNF–α7 nAChR plasticity link, the adolescent-brain risk, the 2025 cerebrovascular study, the HGF/c-Met synaptogenesis case — and why quitting nicotine, not a peptide, clears vape brain fog…

Read the full review →
Cannabis and Weed Brain Fog – Dihexa evidence review
Substance & Lifestyle Neuroscience 14 June 2026

Dihexa for Cannabis & Weed Brain Fog: THC, Working Memory & the 2026 UK Review

“Why is my head so foggy when I smoke — and why won’t it clear now I’ve stopped?” Cannabis is Britain’s most-used illicit drug, and in January 2025 the largest brain-imaging study of its kind (JAMA Network Open, 1,003 adults) found most heavy and recent users showed reduced brain activity during a working-memory task. A 2026 UK review of how THC acts on CB1 receptors and the intertwined endocannabinoid–BDNF system, why cannabis cognition largely recovers after a tolerance break (Scott 2018: deficits fading past ~72 hours), high-potency “skunk” and psychosis, synthetic “Spice” and cannabinoid hyperemesis syndrome, the May 2025 London Drugs Commission decriminalisation report — and why a break comes first, not a peptide…

Read the full review →
Alcohol Brain Fog and Alcohol-Related Brain Damage (ARBD) – Dihexa evidence review
Substance & Lifestyle Neuroscience 11 June 2026

Dihexa for Alcohol Brain Fog & Alcohol-Related Brain Damage (ARBD): The 2026 UK Review

Can a synaptogenic peptide help alcohol brain fog, “sober brain fog” or alcohol-related brain damage? A 2026 UK review of the ONS’s 9,809 UK alcohol-specific deaths in 2024, the 2025 “no safe level” brain-volume and dementia data, how chronic drinking suppresses hippocampal BDNF and adult neurogenesis (with the 2026 Frontiers in Psychiatry proBDNF study), the thiamine/Wernicke–Korsakoff emergency you must not miss, how cognition and hippocampal volume recover in abstinence, the 2025 semaglutide alcohol-use-disorder trial — and why cutting down, thiamine and a medically supervised detox come first, not a peptide…

Read the full review →
Statin Brain Fog – Dihexa evidence review
Pharmacology & Drug-Induced Neuroscience 10 June 2026

Dihexa for Statin Brain Fog: Statins, Memory, Brain Cholesterol & the 2026 UK Review

Do statins cause brain fog — and can a synaptogenic peptide help, or just distract from reviewing the statin? A 2026 UK review of the March 2026 NeuroToxicology study showing rosuvastatin disrupts brain microglia, the FDA’s 2012 “reversible memory loss” label change, the 2025 seven–million–patient meta–analysis finding statin users have lower dementia risk, the brain–cholesterol–to–synapse mechanism (Mauch 2001), lipophilic vs hydrophilic statins and the blood–brain barrier, the nocebo effect, NICE NG238 — and why reviewing the statin with your GP comes first, not a peptide…

Read the full review →

Hormonal Health — Men's & Women's

Hormonal transitions and cognitive change — low testosterone and andropause, menopause, PCOS, thyroid and the maternal brain.

Low Testosterone, Andropause and TRT Brain Fog – Dihexa evidence review on testosterone, memory and focus
NewHormonal & Men’s Health Neuroscience 2 July 2026

Dihexa & Low Testosterone Brain Fog: Low-T, Andropause & TRT (2026 UK Review)

Can a synaptogenic peptide clear low testosterone or “andropause” brain fog? A 2026 UK review tied to the 2026 boom in private TRT clinics: what the Testosterone Trials and the 2025 androgen-therapy meta-analysis found on memory and focus, how testosterone shapes the hippocampus and prefrontal cortex, the dendritic-spine and HGF/c-Met case, the prostate and c-Met cancer concern — and why diagnosing and treating the hormone, not a peptide, comes first…

Read the full review →
Baby Brain, Pregnancy and Postpartum Brain Fog – Dihexa evidence review
Maternal & Hormonal Neuroscience 7 June 2026

Dihexa for Baby Brain, Pregnancy & Postpartum Brain Fog: The 2026 UK Review

Can Dihexa help baby brain, pregnancy brain fog or postpartum "mum brain"? A 2026 UK evidence review of the maternal brain remodelling shown by Hoekzema 2017 and Pritschet 2024, the Davies 2018 cognition meta-analysis, the postpartum estradiol-BDNF crash, allopregnanolone and zuranolone, sleep, thyroid and iron drivers — and why pregnancy and breastfeeding are absolute contraindications…

Read the full review →

Mental Health & Psychiatry

Mood, anxiety and psychiatric conditions.

Dihexa vs ashwagandha for brain fog, cortisol and focus – 2026 UK evidence review on the adaptogen, the cortisol RCTs and the 2025 liver-injury signal
NewAdaptogens, Stress & Cognitive Neuroscience 12 July 2026

Dihexa vs Ashwagandha for Brain Fog, Cortisol & Focus: The 2026 UK Review

Does ashwagandha really clear brain fog and lower cortisol? A 2026 UK review for executives, founders and students: the 2012 RCT showing ~27.9% lower cortisol, the Choudhary 2017 memory trial, the GABA-mimetic and acetylcholinesterase mechanism, why it works best in the stressed, and the real 2025 liver-injury signal — versus Dihexa’s unproven HGF/c-Met synaptogenesis and the c-Met concern. Why the comparison is not close…

Read the full review →
Insomnia and Sleep Deprivation Brain Fog – Dihexa evidence review
Sleep & Cognitive Neuroscience 29 June 2026

Dihexa for Insomnia & Sleep Deprivation Brain Fog: Glymphatics, Synaptic Homeostasis, Daridorexant & the 2026 UK Review

Can a synaptogenic peptide help insomnia or sleep deprivation brain fog? A 2026 UK review of the ~one-third of UK adults with insomnia symptoms, the glymphatic waste-clearance and amyloid link, the synaptic homeostasis hypothesis, why CBT-i and daridorexant (NICE TA922) come first, the BDNF / HGF-c-Met case, the vivid-dreams mismatch — and why fixing sleep, not a peptide, comes first…

Read the full review →
Burnout Brain Fog – Dihexa evidence review
Occupational & Stress Neuroscience 17 June 2026

Dihexa for Burnout Brain Fog: Chronic Work Stress, Cortisol, Cognition & the 2026 UK Review

“I’m so burned out I can’t think straight.” In 2024/25 the HSE recorded a record 964,000 UK workers with work-related stress, depression or anxiety — 22.1 million working days lost — and the Mental Health UK Burnout Report 2026 found 91% had faced high pressure in the past year. Burnout reliably fogs thinking: a 2021 meta-analysis shows it impairs executive function, attention and memory, and chronic stress lowers BDNF, suppresses neurogenesis and thins hippocampal synapses. A 2026 UK review of the WHO ICD-11 definition, the messy cortisol/HPA-axis story (it’s not simply “high cortisol”), the synapse-loss biology, the HGF/c-Met synaptogenesis case — and why rest, recovery and reducing the load come first, not a peptide…

Read the full review →

Neurodegeneration & Dementia

Progressive conditions affecting memory and cognition.

ALS and Motor Neurone Disease (MND) – Dihexa evidence review
Motor Neurone Disease & Neurodegeneration 11 May 2026

Dihexa for ALS & Motor Neurone Disease (MND): The 2026 UK Review

Could Dihexa help ALS / motor neurone disease? A 2026 UK review: 5,000 UK patients, HGF/c-Met motor neuron protection, Engensis (VM202), the May 2026 Longitude Prize on ALS, EXPERTS-ALS, MND-SMART,…

Read the full review →

Sleep, Circadian, Injury & Neuro-Rehab

Sleep and body-clock disruption, and recovery after injury, treatment or sensory damage.

Jet Lag and Travel Brain Fog – Dihexa evidence review on circadian disruption, memory, cortisol and melatonin
NewSleep, Circadian & Cognitive Neuroscience 10 July 2026

Dihexa for Jet Lag & Travel Brain Fog: Circadian Disruption, Memory & the 2026 UK Review

A rare brain fog with rock-solid science: crossing time zones measurably impairs memory, attention and decision-making because you are thinking during your biological night. A 2026 UK review for business travellers, executives and students — the CDC Yellow Book 2026 jet-lag-disorder definition, the Cho 2001 cabin-crew cortisol and temporal-lobe study, the hippocampal-neurogenesis mechanism, light timing and melatonin — and why a self-correcting body-clock glitch is no place for a c-Met peptide…

Read the full review →
Peripheral Neuropathy and Nerve Regeneration – Dihexa evidence review
Regenerative Neuroscience & Peripheral Nerve Repair 12 June 2026

Dihexa for Peripheral Neuropathy & Nerve Regeneration: HGF/c-Met, Schwann Cells, Diabetic & Chemo Neuropathy — The 2026 UK Review

Most Dihexa interest is about the brain — but the HGF/c-Met pathway it targets is also a master regulator of peripheral nerve repair. A 2026 UK review of how HGF activates “repair” Schwann cells (Ko 2018, Scientific Reports), the 2021 rat sciatic-nerve study where Dihexa + stem cells improved motor recovery, the VM202 / Engensis HGF gene-therapy Phase 3 in painful diabetic peripheral neuropathy (results posted Jan 2025), chemotherapy-induced neuropathy (CIPN) and the duloxetine question, and the 2026 Athira→LeonaBio pivot taking the oral HGF/MET modulator ATH-1105 into ALS — with an honest account of why Dihexa still has zero human neuropathy data…

Read the full review →
Migraine and Chronic Migraine – Dihexa evidence review
Neuroscience 27 May 2026

Dihexa for Migraine & Chronic Migraine: The 2026 UK Review

Rigorous 2026 UK review of Dihexa for migraine and chronic migraine. Covers the 10 million UK adults with migraine (~1 million chronic) on Migraine Trust 2026 figures, the May 2024 NICE TA973…

Read the full review →
Insomnia and Sleep Deprivation Brain Fog – Dihexa evidence review
Sleep & Cognitive Neuroscience 29 June 2026

Dihexa for Insomnia & Sleep Deprivation Brain Fog: The Glymphatic System, Synaptic Homeostasis, Daridorexant & the 2026 UK Review

Sleep loss is one of the most powerful causes of brain fog there is, and roughly one in three UK adults reports insomnia symptoms. A 2026 UK review of the glymphatic and synaptic-homeostasis science, why CBT-i and daridorexant (Quviviq, NICE TA922) come first, the BDNF / HGF/c-Met case and the vivid-dreams mismatch…

Read the full review →

Core Science & Nootropics

The mechanism, the evidence and how Dihexa is used.

Dihexa vs Alpha-GPC (choline alfoscerate) for memory, focus and brain fog – 2026 UK evidence review on the choline cholinergic, the ASCOMALVA trial, the stroke question and the HGF/c-Met peptide
NewNootropics, Memory & Cognitive Neuroscience 18 July 2026

Dihexa vs Alpha-GPC for Memory, Focus & Brain Fog: The 2026 UK Review

Does Alpha-GPC (choline alfoscerate) — the choline in every focus stack and pre-workout — sharpen memory and focus? A 2026 UK review of the acetylcholine mechanism, the ASCOMALVA Alzheimer’s trial, the Ziegenfuss 2008 gym study, the 2025 dementia data and the unresolved stroke question — versus Dihexa’s unproven HGF/c-Met synaptogenesis and the c-Met concern.

Read the full review →
Dihexa vs Bacopa monnieri (Brahmi) for memory, brain fog and focus – 2026 UK evidence review on the best-evidenced herbal memory aid, the 12-week curve and the HGF/c-Met peptide question
NewNootropics, Memory & Cognitive Neuroscience 16 July 2026

Dihexa vs Bacopa Monnieri for Memory, Brain Fog & Focus: The 2026 UK Review

Does Bacopa monnieri (Brahmi) improve memory and clear brain fog? The best-evidenced herbal memory aid: the Stough 2001 12-week RCT, the Kongkeaw 2014 meta-analysis, the bacoside / cholinergic / dendritic mechanism, the 300 mg dose and 8–12 week timeline — versus Dihexa’s unproven HGF/c-Met synaptogenesis and the c-Met concern. Why the memory herb wins.

Read the full review →
Best nootropics for studying, focus and memory – 2026 UK guide covering the caffeine + L-theanine stack, creatine, study drugs and where Dihexa fits
NewNootropics, Focus & Cognitive Neuroscience 15 July 2026

Best Nootropics for Studying, Focus & Memory: The 2026 UK Guide

Which nootropic actually helps you study harder, focus longer and remember more? An evidence-based 2026 UK guide for students, CEOs and high performers, ranking every option by human proof: the caffeine + L-theanine stack, creatine, omega-3, the prescription study drugs (modafinil), the racetam/peptide tier — and why Dihexa, with no human study data, is not a study aid.

Read the full guide →
Dihexa vs L-theanine for brain fog, focus and calm – 2026 UK evidence review on the calm-focus amino acid, the caffeine stack and the HGF/c-Met peptide question
NewNootropics, Focus & Cognitive Neuroscience 13 July 2026

Dihexa vs L-Theanine for Brain Fog, Focus & Calm: The 2026 UK Review

Does L-theanine — the calm-focus amino acid in tea — clear brain fog and sharpen focus? A 2026 UK review of the Molecular Psychiatry meta-analysis of 31 trials, the 2:1 caffeine + L-theanine stack, the alpha-wave and GABA mechanism, the sleep and stress data, the honest EFSA caveat and its excellent safety — versus Dihexa’s unproven HGF/c-Met synaptogenesis and the c-Met concern. Why the tea amino acid wins…

Read the full review →
Dihexa vs Methylene Blue for Brain Fog and Cognitive Energy – 2026 evidence review on the mitochondrial nootropic, the fMRI memory study and the FDA serotonin warning
NewBrain Energy & Nootropics 11 July 2026

Dihexa vs Methylene Blue for Brain Fog & Cognitive Energy: The 2026 UK Review

Methylene blue or Dihexa for brain fog? A 2026 UK review of the viral mitochondrial nootropic: the 2016 Radiology fMRI memory study (~7% retrieval boost), the electron-transport-chain / cytochrome-c-oxidase mechanism, the TauRx hydromethylthionine Alzheimer’s Phase 3 and 2024 MHRA application, and the FDA serotonin-syndrome warning — versus Dihexa’s unproven HGF/c-Met synaptogenesis and the c-Met concern. Why hype is not evidence.

Read the full review →
Dihexa vs Creatine for Brain Fog and Cognitive Energy – Dihexa evidence review on creatine, phosphocreatine and memory
NewBrain Energy & Nootropics 3 July 2026

Dihexa vs Creatine for Brain Fog & Cognitive Energy: The 2026 UK Review

Creatine or Dihexa for cognitive energy? A 2026 UK review of the 2024 sleep-deprivation study, the 2025 Alzheimer’s creatine pilot, the memory meta-analyses and the phosphocreatine “backup battery” — versus Dihexa’s unproven HGF/c-Met synaptogenesis and the c-Met concern. Why the cheap, safe, evidence-backed option comes first.

Read the full review →